Delivery apps are allowing Chinese citizens to get their hands on the popular weight-loss and diabetes drugs at the touch of ...
Ozempic side effects that are more common in females vs. males include nausea, vomiting, dizziness, and headache. Females ...
Pharmalittle: We’re reading about Zepbound price and dose changes, compounders suing FDA, and more
Eli Lilly will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells ...
The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...
Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Pfizer appoints Patrizia Cavazzoni as chief medical officer, the U.S. delays the definition of 'healthy' on labels, issues ...
The lawsuit claims the FDA's finding that there was no longer a shortage of the drugs' active ingredient semaglutide was ...
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback